Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  O'Bryan, Joel M ^a   Potts, James A ^a   Bonkovsky, Herbert L ^b,c   Mathew, Anuja ^a   Rothman, Alan L ^a,d   for the HALT C Trial Group, ^e  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; CD45RA ANTIGEN; CD57 ANTIGEN; PEGYLATED INTERFERON ALPHA; PEGYLATED INTERFERON ALPHA PLUS RIBAVIRIN; UNCLASSIFIED DRUG; ASPARTATE AMINOTRANSFERASE; LEUKOCYTE ANTIGEN; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SCREENING; CHROMOSOME LOSS; CHROMOSOME SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; MALE; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TELOMERE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOLOGY; ULTRASTRUCTURE;

HEPATITIS C VIRUS;

ALANINE TRANSAMINASE; ANTIGENS, CD; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HEPATITIS C; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON-ALPHA; RIBAVIRIN; T-LYMPHOCYTES; TELOMERE; VIRAL LOAD;

EID: 79961141338     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020922     Document Type: Article

References (44)

1. de Lange T, (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19: 2100-2110.
2. Hodes RJ, Hathcock KS, Weng NP, (2002) Telomeres in T and B cells. Nat Rev Immunol 2: 699-706.
3. Weng NP, (2008) Telomere and adaptive immunity. Mech Ageing Dev 129: 60-66.
4. Xu D, Erickson S, Szeps M, Gruber A, Sangfelt O, et al. (2000) Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 96: 4313-4318.
5. Hirsch RL, Johnson KP, (1986) The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis. J Interferon Res 6: 171-177.
6. Boyman O, Letourneau S, Krieg C, Sprent J, (2009) Homeostatic proliferation and survival of naive and memory T cells. Eur J Immunol 39: 2088-2094.
7. Hoofnagle JH, Seeff LB, (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355: 2444-2451.
8. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, et al. (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136: 138-148.
9. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, et al. (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359: 2429-2441.
10. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, et al. (2004) Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25: 472-492.
11. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, et al. (2009) Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 137: 549-557.
12. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, et al. (1999) Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 30: 1307-1311.
13. Lin R, Liddle C, Byth K, Farrell GC, (1996) Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat 3: 85-96.
14. Romeo R, Rumi M, Colombo M, (1995) Alpha interferon treatment of chronic hepatitis C. Biomed Pharmacother 49: 111-115.
15. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, et al. (2005) Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 41: 617-625.
16. Vandelli C, Renzo F, Braun HB, Tisminetzky S, Albrecht M, et al. (1999) Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C. J Med Virol 58: 26-34.
17. Tillmann HL, Manns MP, Rudolph KL, (2005) Merging models of hepatitis C virus pathogenesis. Semin Liver Dis 25: 84-92.
18. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, et al. (2005) Obesity, cigarette smoking, and telomere length in women. Lancet 366: 662-664.
19. Zannolli R, Mohn A, Buoni S, Pietrobelli A, Messina M, et al. (2008) Telomere length and obesity. Acta Paediatr 97: 952-954.
20. O'Callaghan NJ, Clifton PM, Noakes M, Fenech M, (2009) Weight loss in obese men is associated with increased telomere length and decreased abasic sites in rectal mucosa. Rejuvenation Res 12: 169-176.
21. Baerlocher GM, Vulto I, de Jong G, Lansdorp PM, (2006) Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 1: 2365-2376.
22. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J, (2007) Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 318: 798-801.
23. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, et al. (2008) Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing 5: 6.
24. Weng NP, Levine BL, June CH, Hodes RJ, (1995) Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc Natl Acad Sci U S A 92: 11091-11094.
25. Aubert G, Lansdorp PM, (2008) Telomeres and aging. Physiol Rev 88: 557-579.
26. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, et al. (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101: 2711-2720.
27. Le Priol Y, Puthier D, Lecureuil C, Combadiere C, Debre P, et al. (2006) High cytotoxic and specific migratory potencies of senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals. J Immunol 177: 5145-5154.
28. Manfras BJ, Weidenbach H, Beckh KH, Kern P, Moller P, et al. (2004) Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy. J Clin Immunol 24: 258-271.
29. De Boer RJ, Noest AJ, (1998) T cell renewal rates, telomerase, and telomere length shortening. J Immunol 160: 5832-5837.
30. Hotamisligil GS, Erbay E, (2008) Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 8: 923-934.
31. Dixit VD, (2008) Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J Leukoc Biol 84: 882-892.
32. Gilley D, Herbert BS, Huda N, Tanaka H, Reed T, (2008) Factors impacting human telomere homeostasis and age-related disease. Mech Ageing Dev 129: 27-34.
33. Farzaneh-Far R, Lin J, Epel E, Lapham K, Blackburn E, et al. (2009) Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study. PLoS One 5: e8612.
34. Huzen J, de Boer RA, van Veldhuisen DJ, van Gilst WH, van der Harst P, (2010) The emerging role of telomere biology in cardiovascular disease. Front Biosci 15: 35-45.
35. Zee RY, Michaud SE, Germer S, Ridker PM, (2009) Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. Clin Chim Acta 403: 139-141.
36. Reed JR, Vukmanovic-Stejic M, Fletcher JM, Soares MV, Cook JE, et al. (2004) Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med 199: 1433-1443.
37. Hoare M, Gelson WT, Das A, Fletcher JM, Davies SE, et al. (2010) CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. J Hepatol 53: 252-260.
38. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, et al. (2002) Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 36: 1273-1279.
39. Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, et al. (2008) Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 36: 250-255.
40. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 53: 1100-1108.
41. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, et al. (2008) Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112: 982-994.
42. Lam S, Wang S, Gottesman M, (2008) Interferon-beta1b for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol 4: 1111-1117.
43. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, et al. (2010) Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 8: 458-462.
44. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, et al. (2010) Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 51: 585-594.